Best Tesamorelin stacks for fat reduction, recovery, and HGH optimisation

The best tesamorelin stacks are usually built around peptides or therapies that support growth hormone (GH) activity, regeneration, body composition, and metabolic health without overly stimulating the GH–IGF-1 axis. Tesamorelin itself is already a potent growth hormone-releasing hormone (GHRH) analogue with well-documented effects in visceral fat reduction and improvement of metabolic markers [1–6]. Most additional combinations, however, are primarily based on theoretical synergy, smaller studies, or practices used in wellness and biohacking settings, rather than large clinical trials evaluating specific peptide „stacks.” For this reason, such combinations should be approached with caution and ideally under the guidance of a specialist.

Tesamorelin works by stimulating GHRH receptors in the pituitary gland, increasing natural, pulsatile secretion of GH and raising levels of insulin-like growth factor-1 (IGF-1) [1,2]. Clinical studies show that this can lead to a reduction in visceral fat, improvement in fatty liver, support for lean body mass, and improved lipid metabolism [3–6]. As tesamorelin already strongly activates the GHRH pathway, the most popular stacks usually aim to supplement its action rather than replicate it.

One of the most discussed combinations is the tesamorelin and ipamorelin stack. Ipamorelin is a growth hormone secretagogue (GHS) peptide and a ghrelin receptor agonist that stimulates GH release through a different mechanism than tesamorelin [7–10]. Tesamorelin acts via GHRH receptors, whereas ipamorelin activates ghrelin receptors (GHS-R1a). As both peptides affect different parts of the growth hormone regulatory system, some people believe that their combination may support stronger or more natural GH pulsations.

Ipamorelin is often considered one of the more selective GH secretagogues, as it causes less cortisol and prolactin release compared to older GHRP peptides [7,8]. Although large clinical trials directly analysing the tesamorelin and ipamorelin stack are currently lacking, the scientific rationale for such a combination is considered biologically plausible.

In terms of body composition, tesamorelin has significantly stronger clinical evidence regarding the reduction of visceral fat and the improvement of metabolic health. Clinical studies have repeatedly demonstrated a reduction in visceral fat of approximately 15–18% during tesamorelin therapy [3–5]. Research on ipamorelin, however, focuses mainly on GH secretion, recovery, sleep quality and anabolic signalling, rather than directly on the effects of fat reduction [7–10]. For this reason, tesamorelin is usually regarded as the main component of a stack responsible for fat reduction and the improvement of metabolic parameters.

Another frequently discussed combination is tesamorelin with testosterone replacement therapy (TRT). Both therapies act through different hormonal systems and can provide complementary effects on body composition. Tesamorelin primarily focuses on visceral fat reduction and activation of the GH–IGF-1 axis, while TRT supports muscle protein synthesis, strength, libido, energy levels, and bone density. Clinical studies show that tesamorelin improves visceral fat mass, liver steatosis, triglycerides, and metabolic markers without significant deterioration of glycaemic control [3–6]. However, large randomised trials investigating the concurrent use of tesamorelin and TRT are still lacking.

Some individuals also combine tesamorelin with peptides that support regeneration, such as BPC-157 or TB-500, particularly within sports and wellness settings. However, it should be emphasised that high-quality clinical research on such combinations is virtually non-existent. Most available information stems from animal studies, experimental peptide literature, or anecdotal reports, rather than controlled clinical trials. From a scientific perspective, the most robust evidence for tesamorelin continues to relate to visceral fat reduction, improvement in fatty liver disease, and metabolic health, rather than extreme muscle mass gain.

It is also worth understanding that combining multiple GH-stimulating peptides may increase the risk of adverse effects associated with elevated GH and IGF-1 activity. Adverse effects reported in studies on tesamorelin included:

• Water retention and swelling
• Joint stiffness or pain
• Injection site reactions
• Numbness or tingling
• reddening of the skin
• elevated IGF-1 levels [3–6]

Similar adverse effects may also occur when using ipamorelin and other GH secretagogues [7-10]. Excessive stimulation of the GH-IGF-1 axis can increase the risk of insulin resistance, fluid retention, or hormonal disorders in some individuals. For this reason, combining several GH peptides at full doses does not always provide additional benefits proportional to the potential risks.

From an evidence-based medicine perspective, tesamorelin itself currently has significantly stronger clinical support than most peptide stacks promoted in the context of anti-aging, HGH optimisation, or bodybuilding. Human studies have consistently shown reductions in visceral fat, improvement in fatty liver, beneficial effects on lipid profiles, support for mitochondrial function, and preservation of muscle tissue [3–6]. Additional combinations may theoretically offer complementary benefits; however, their clinical confirmation remains limited.

Generally speaking, the best stack with tesamorelin depends on the objective. For visceral fat reduction and improved metabolic health, tesamorelin alone already has strong clinical evidence. In broader protocols aimed at GH optimisation and recovery, combinations like tesamorelin with ipamorelin are sometimes considered, as both peptides stimulate different pathways regulating GH secretion. However, most such stacks remain experimental, and the long-term safety of combining multiple GH secretagogues has not yet been fully established in human clinical trials.

Disclaimer

This content is for educational and informational purposes only and does not constitute medical, diagnostic or therapeutic advice. Tesamorelin is a prescription medicine approved for specific medical indications, whereas many of the peptide combinations discussed online remain experimental or are used off-label. Peptides affecting growth hormone and IGF-1 pathways may carry risks, including oedema, insulin resistance, hormonal disturbances and elevated IGF-1 levels. Any hormone or peptide therapy should only be undertaken under the supervision of a qualified specialist with appropriate laboratory monitoring. Research-use-only peptides offered by suppliers such as Semax Polska are intended solely for laboratory and scientific research.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/
2. PubChem. (2025). Tesamorelin Compound Summary. National Centre for Biotechnology Information, National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
3. Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
4. Falutz, J., Allas, S., Mamputu, J. C., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
5. Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomised clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
6. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Agyapong, G., Torriani, M., Chung, R. T., & Grinspoon, S. K. (2019). Effect of tesamorelin on non-alcoholic fatty liver disease in HIV-positive individuals: A randomised, double-blind, multicentre study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
7. Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/A:1018955126402
8. Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976
9. Johansen, P. B., Nowak, J., Skjaerbaek, C., Pedersen, S. B., Flyvbjerg, A., & Andreassen, T. T. (1999). Ipamorelin, a new growth hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106–113. https://doi.org/10.1054/ghir.1999.9998
10. Jiménez-Reina, L., Cañete, R., de la Torre, M. J., & Bernal, G. (2002). Effect of chronic treatment with the growth hormone secretagogue ipamorelin in young female rats: In vitro somatotropic response. Histology and Histopathology, 17(3), 707–714. https://doi.org/10.14670/HH-17.707